157 related articles for article (PubMed ID: 36095125)
1. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry.
Buckstein R; Chodirker L; Mozessohn L; Yee KWL; Geddes M; Zhu N; Shamy A; Leitch HA; Christou G; Banerji V; Brian L; Khalaf D; St-Hilaire E; Finn N; Nevill T; Keating MM; Storring J; Delage R; Parmentier A; Thambipillai A; Siddiqui M; Westcott C; Cameron C; Mamedov A; Spin P; Tang D
Leuk Lymphoma; 2022 Dec; 63(13):3165-3174. PubMed ID: 36095125
[TBL] [Abstract][Full Text] [Related]
2. The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry.
Buckstein R; Chodirker L; Yee KWL; Geddes M; Leitch HA; Christou G; Banerji V; Leber B; Khalaf D; St-Hilaire E; Finn N; Nevill T; Keating MM; Storring J; Parmentier A; Thambipillai A; Tang D; Westcott C; Cameron C; Spin P
Leuk Lymphoma; 2023 Mar; 64(3):651-661. PubMed ID: 36606533
[TBL] [Abstract][Full Text] [Related]
3. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
[TBL] [Abstract][Full Text] [Related]
4. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
5. Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM).
Jouzier C; Cherait A; Cony-Makhoul P; Hamel JF; Veloso M; Thepot S; Cluzeau T; Stamatoullas A; Garnier A; Guerci-Bresler A; Dimicoli-Salazar S; Pica GM; Cheze S; Santana C; Chermat F; Fenaux P; Park S
Transfusion; 2022 May; 62(5):961-973. PubMed ID: 35452143
[TBL] [Abstract][Full Text] [Related]
6. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.
Hoeks M; Yu G; Langemeijer S; Crouch S; de Swart L; Fenaux P; Symeonidis A; Čermák J; Hellström-Lindberg E; Sanz G; Stauder R; Holm MS; Mittelman M; Mądry K; Malcovati L; Tatic A; Almeida AM; Germing U; Savic A; Šimec NG; Culligan D; Itzykson R; Guerci-Bresler A; Slama B; Droste J; van Marrewijk C; van de Loosdrecht A; Blijlevens N; van Kraaij M; Bowen D; de Witte T; Smith A;
Haematologica; 2020 Mar; 105(3):640-651. PubMed ID: 31278207
[TBL] [Abstract][Full Text] [Related]
7. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
8. New Approaches to Myelodysplastic Syndrome Treatment.
Bazinet A; Bravo GM
Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
[TBL] [Abstract][Full Text] [Related]
9. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
10. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
11. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
[TBL] [Abstract][Full Text] [Related]
12. Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Mądry K; Lis K; Fenaux P; Bowen D; Symeonidis A; Mittelman M; Stauder R; Čermák J; Sanz G; Hellström-Lindberg E; Langemeijer S; Malcovati L; Germing U; Holm MS; Guerci-Bresler A; Culligan D; Sanhes L; Kotsianidis I; van Marrewijk C; Crouch S; de Witte T; Smith A;
Br J Haematol; 2023 Feb; 200(4):451-461. PubMed ID: 36335984
[TBL] [Abstract][Full Text] [Related]
13. SF3B1-mutated myelodysplastic syndrome with ring sideroblasts harbors more severe iron overload and corresponding over-erythropoiesis.
Zhu Y; Li X; Chang C; Xu F; He Q; Guo J; Tao Y; Liu Y; Liu L; Shi W
Leuk Res; 2016 May; 44():8-16. PubMed ID: 26970172
[TBL] [Abstract][Full Text] [Related]
14. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study.
Platzbecker U; Germing U; Götze KS; Kiewe P; Mayer K; Chromik J; Radsak M; Wolff T; Zhang X; Laadem A; Sherman ML; Attie KM; Giagounidis A
Lancet Oncol; 2017 Oct; 18(10):1338-1347. PubMed ID: 28870615
[TBL] [Abstract][Full Text] [Related]
15. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.
Lyons RM; Marek BJ; Paley C; Esposito J; McNamara K; Richards PD; DiBella N; Garcia-Manero G
Leuk Res; 2017 May; 56():88-95. PubMed ID: 28242540
[TBL] [Abstract][Full Text] [Related]
16. [Myelodysplastic syndromes and iron metabolism].
Kawabata H
Rinsho Ketsueki; 2018; 59(10):2042-2049. PubMed ID: 30305507
[TBL] [Abstract][Full Text] [Related]
17. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010.
Dinmohamed AG; Visser O; van Norden Y; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Eur J Cancer; 2014 Mar; 50(5):1004-12. PubMed ID: 24388662
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts.
Mangaonkar AA; Gangat N; Al-Kali A; Elliott MA; Begna KH; Hanson CA; Ketterling RP; Wolanskyj-Spinner AP; Hogan WJ; Litzow MR; Patnaik MM
Leuk Res; 2018 Aug; 71():60-62. PubMed ID: 30015104
[TBL] [Abstract][Full Text] [Related]
19. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
[TBL] [Abstract][Full Text] [Related]
20. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
